Specifically, hyperuricosuria, in conjunction with the hyperglycosuria effect of SGLT2 inhibitors, synergistically contributes to the development of urinary tract infections [43], as was evident by occurrences of urinary tract infections in four patients in the EMPA group. The gene discussed is SLC5A2; the disease is urinary tract infection.